Device Trial Radar · NCT04004169
Closed-Loop Deep Brain Stimulation for Major Depression
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 18, 2019
Primary completion
Jun 28, 2030
Study completion Jun 28, 2035
Sponsor
- Lead sponsor
- Andrew KrystalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to help alter the communication between groups of neurons in the brain. The purpose of this study is to test a personalized approach to brain stimulation as an intervention for depression. The study researchers will use a surgically implanted device to measure each individual's brain activity related to his/her depression. The researchers will then use small electrical impulses to alter that brain activity and measure whether these changes help reduce depression symptoms. This study is intended for patients with major depression whose symptoms have not been adequately treated with currently available therapies. The device used in this study is called the NeuroPace Responsive Neurostimulation (RNS) System. It is currently FDA approved to treat patients with epilepsy. The study will test whether personalized responsive neurostimulation can safely and effectively treat depression.
Conditions
- Major Depressive Disorder
Interventions
Stimulation-ONDevice
Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
Stimulation-OFFDevice
No neurostimulation from the NeuroPace RNS® System
Stimulation-ON Active ControlDevice
Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in MADRS scoreTime frame: administered at baseline and every 2 weeks for the first 18 weeks of stage 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.